A Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway

Status:
Enrolling by invitation

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Phase 3 trial to compare the weekly and daily formulations of setmelanotide in patients with genetic defects in the melanocortin-4 receptor pathway.

Phase 3

Rhythm Pharmaceuticals, Inc.

alpha-MSH